NOVAVAX INC (NVAX) Current Ratio
- Current ratio · latest quarter: Value 2.33×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.33× | Current assets / current liabilities. $771.10M ÷ $330.57M ≈ 2.33× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 771.10M USD | Assets, Current |
| Current obligations | 330.57M USD | Liabilities, Current |
| Cash and equivalents | 191.46M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 527.88M USD | Marketable Securities, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 10.01M USD | Inventory, Net |
| Payables | 22.94M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $771.10M | $330.57M | $191.46M | $527.88M | (m) | $10.01M | $22.94M | (m) | 2.33× |
| 2026-03-31 | $850.82M | $342.46M | $228.36M | $561.97M | (m) | $11.46M | $16.10M | (m) | 2.48× |
| 2025-12-31 | $978.28M | $459.95M | $240.63M | $494.45M | (m) | $11.54M | $24.58M | (m) | 2.13× |
| 2025-09-30 | $974.59M | $429.87M | $268.02M | $494.87M | (m) | $13.51M | $15.23M | (m) | 2.27× |
| 2025-06-30 | $919.51M | $389.14M | $253.74M | $358.56M | (m) | $10.24M | $50.59M | (m) | 2.36× |
| 2025-03-31 | $868.03M | $422.17M | $263.34M | $468.14M | (m) | $10.26M | $34.16M | (m) | 2.06× |
| 2024-12-31 | $1.13B | $1.15B | $530.23M | $392.89M | (m) | $8.75M | $41.58M | (m) | 0.98× |
| 2024-09-30 | $1.10B | $1.18B | $573.63M | $335.90M | (m) | $8.64M | $57.52M | (m) | 0.93× |
| 2024-06-30 | $1.20B | $1.16B | $680.16M | $369.43M | (m) | $9.17M | $79.96M | (m) | 1.04× |
| 2024-03-31 | $727.12M | $804.38M | $480.59M | (m) | (m) | $15.78M | $57.72M | (m) | 0.90× |
| 2023-12-31 | $1.14B | $1.64B | $568.50M | $0.00 | (m) | $41.70M | $132.61M | (m) | 0.70× |
| 2023-09-30 | $1.01B | $1.47B | $651.10M | (m) | (m) | $69.59M | $101.91M | (m) | 0.69× |
| 2023-06-30 | $1.13B | $1.60B | $505.91M | (m) | (m) | $23.49M | $87.25M | (m) | 0.71× |
| 2023-03-31 | $971.03M | $1.92B | $624.95M | (m) | (m) | $34.19M | $124.80M | (m) | 0.51× |
| 2022-12-31 | $1.70B | $2.46B | $1.34B | (m) | (m) | $36.68M | $216.52M | (m) | 0.69× |
| 2022-09-30 | $1.76B | $1.67B | $1.28B | (m) | (m) | $82.43M | $145.00M | (m) | 1.06× |
| 2022-06-30 | $2.14B | $2.16B | $1.38B | (m) | (m) | $256.30M | $386.49M | (m) | 0.99× |
| 2022-03-31 | $2.35B | $2.26B | $1.57B | (m) | (m) | $106.65M | $135.13M | (m) | 1.04× |
| 2021-12-31 | $2.16B | $2.39B | $1.52B | (m) | (m) | $8.87M | $127.05M | (m) | 0.90× |
| 2021-09-30 | $2.17B | $1.75B | $1.94B | $0.00 | (m) | (m) | $59.56M | (m) | 1.24× |
| 2021-06-30 | $2.35B | $1.65B | $2.07B | $0.00 | (m) | (m) | $74.00M | (m) | 1.43× |
| 2021-03-31 | $2.25B | $1.21B | $2.00B | $2.25M | (m) | (m) | $113.61M | (m) | 1.86× |
| 2020-12-31 | $1.25B | $579.67M | $553.40M | $157.65M | (m) | (m) | $54.33M | (m) | 2.15× |
| 2020-09-30 | $671.22M | $239.22M | $334.17M | $169.86M | (m) | (m) | $15.10M | (m) | 2.81× |
| 2020-06-30 | $636.38M | $213.33M | $424.39M | $77.90M | (m) | (m) | $9.24M | (m) | 2.98× |
| 2020-03-31 | $255.23M | $18.98M | $179.88M | $57.47M | (m) | (m) | $2.52M | (m) | 13.45× |
| 2019-12-31 | $97.25M | $25.80M | $78.82M | $0.00 | (m) | (m) | $2.91M | (m) | 3.77× |
| 2019-09-30 | $89.02M | $21.57M | $71.17M | $0.00 | (m) | (m) | $4.21M | (m) | 4.13× |
| 2019-06-30 | $110.22M | $41.49M | $72.00M | $0.00 | (m) | (m) | $4.30M | (m) | 2.66× |
| 2019-03-31 | $123.39M | $31.50M | $97.71M | $2.48M | (m) | (m) | $6.15M | (m) | 3.92× |
| 2018-12-31 | $119.28M | $45.54M | $70.15M | $21.98M | (m) | (m) | $9.30M | (m) | 2.62× |
| 2018-09-30 | $160.54M | $46.72M | $56.50M | $70.61M | (m) | (m) | $6.79M | (m) | 3.44× |
| 2018-06-30 | $194.34M | $43.02M | $88.47M | $78.64M | (m) | (m) | $6.69M | (m) | 4.52× |
| 2018-03-31 | $181.03M | $44.90M | $113.40M | $30.36M | (m) | (m) | $5.77M | (m) | 4.03× |
| 2017-12-31 | $203.31M | $73.67M | $106.31M | $51.00M | (m) | (m) | $5.61M | (m) | 2.76× |
| 2017-09-30 | $226.00M | $68.28M | $104.25M | $68.32M | (m) | (m) | $5.24M | (m) | 3.31× |
| 2017-06-30 | $236.68M | $66.79M | $75.79M | $111.52M | (m) | (m) | $8.02M | (m) | 3.54× |
| 2017-03-31 | $258.45M | $56.50M | $95.85M | $115.33M | (m) | (m) | $3.79M | (m) | 4.57× |
| 2016-12-31 | $287.83M | $66.41M | $144.35M | $91.13M | (m) | (m) | $5.68M | (m) | 4.33× |
| 2016-09-30 | $353.90M | $75.68M | $119.95M | $180.34M | $591.00K | (m) | $16.23M | (m) | 4.68× |
| 2016-06-30 | $419.98M | $81.88M | $89.39M | $276.97M | $363.00K | (m) | $15.99M | (m) | 5.13× |
| 2016-03-31 | $484.60M | $71.05M | $132.22M | $301.64M | $406.00K | (m) | $11.24M | (m) | 6.82× |
| 2015-12-31 | $287.26M | $76.49M | $93.11M | $137.55M | $2.32M | (m) | $11.89M | (m) | 3.76× |
| 2015-09-30 | $310.10M | $24.87M | $138.14M | $152.04M | $2.20M | (m) | $8.20M | (m) | 12.47× |
| 2015-06-30 | $332.98M | $27.05M | $167.38M | $147.55M | $2.34M | (m) | $7.12M | (m) | 12.31× |
| 2015-03-31 | $350.09M | $28.78M | $215.05M | $112.69M | $6.67M | (m) | $9.74M | (m) | 12.17× |
| 2014-12-31 | $188.16M | $34.12M | $32.34M | $135.72M | $7.51M | (m) | $12.91M | (m) | 5.52× |
| 2014-09-30 | $191.98M | $18.64M | $34.47M | $143.62M | $2.86M | (m) | $2.98M | (m) | 10.30× |
| 2014-06-30 | $166.60M | $17.48M | $103.86M | $48.60M | $3.72M | (m) | $4.50M | (m) | 9.53× |
| 2014-03-31 | $128.87M | $13.71M | $109.92M | $2.91M | $4.47M | (m) | $4.02M | (m) | 9.40× |
| 2013-12-31 | $145.00M | $18.12M | $119.47M | $13.60M | $1.91M | (m) | $5.99M | (m) | 8.00× |
| 2013-09-30 | $155.02M | $14.26M | $122.49M | $23.92M | $1.91M | (m) | $3.34M | (m) | 10.87× |
| 2013-06-30 | $45.37M | $11.26M | $2.57M | $38.02M | $907.00K | (m) | $2.95M | (m) | 4.03× |
| 2013-03-31 | $51.72M | $9.25M | $9.02M | $35.26M | $2.60M | (m) | $2.17M | (m) | 5.59× |
| 2012-12-31 | $50.41M | $11.68M | $17.40M | $26.71M | $1.01M | (m) | $3.23M | (m) | 4.32× |
| 2012-09-30 | $36.48M | $10.44M | $10.74M | $17.67M | $2.47M | (m) | $2.20M | (m) | 3.49× |
| 2012-06-30 | $34.98M | $9.42M | $15.33M | $11.20M | $1.50M | (m) | $3.38M | (m) | 3.71× |
| 2012-03-31 | $26.44M | $7.84M | $13.87M | $6.85M | $1.73M | (m) | $2.96M | (m) | 3.37× |
| 2011-12-31 | $26.11M | $7.58M | $14.10M | $4.21M | $1.97M | (m) | $2.65M | (m) | 3.44× |
| 2011-09-30 | $26.25M | $6.74M | $14.32M | $5.29M | $17.00K | (m) | $2.40M | (m) | 3.89× |
| 2011-06-30 | $28.42M | $8.99M | $13.09M | $9.23M | $1.83M | (m) | $2.96M | (m) | 3.16× |
| 2010-12-31 | $33.34M | $10.27M | $8.06M | $23.61M | $54.00K | (m) | $3.57M | (m) | 3.25× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |